Thomas almqvist shen men

Incorporated in England and Wales, registered number 4978912, and registered as a charity in England and Wales, number 1101332.

Possibly Ineffective for:

Improving mental development or growth in infants. Adding arachidonic acid (an omega-6 fatty acid) to infant formula does not seem to improve mental development or growth in infants up to 18 months old.
Multiple sclerosis (MS). Taking omega-6 fatty acids does not seem to prevent the progression of MS.

Insufficient Evidence for:

Attention deficit-hyperactivity disorder ( ADHD ). Early research suggests that taking a combination of omega-3 and omega-6 fatty acids twice daily for 3-6 months does not improve symptoms of ADHD in most children.
Eyelid swelling due to a problem with oil glands in the eyelids. Early research suggests that taking a specific product (Medilar Fidia Oftal Bausch & Laomb Pharmaceuticals) that contains omega-6 fatty acids once daily for 180 days along with cleaning the eyelids can improve cloudiness in the eyes , blockage of the oil glands, and eyelid swelling in people with an eyelid swelling due to a problem with oil glands in the eyelid.
Developmental coordination disorder (DCD). Early research suggests that taking a combination of omega-6 and omega-3 fatty acids for 3 months can improve reading, spelling, and behavior, but not coordination or movement in children with DCD.
Laser eye surgery. Early research suggests that taking a tablet that contains an omega-6 fatty acid, as well as beta-carotene and other ingredients, can improve tear production and improve eye healing after laser eye surgery.
Reducing the risk of heart disease .
Lowering bad cholesterol levels ( LDL ).
Increasing good cholesterol levels (HDL).
Reducing the risk of cancer .
Other conditions.

More evidence is needed to rate the effectiveness of omega-6 fatty acids for these uses.